Insider Trading Activity AnaptysBio Inc (NASDAQ:ANAB) – Major Shareholder Sold 491,294 shares of Stock

0

Insider Trading Activity For AnaptysBio Inc (NASDAQ:ANAB)

Holdings A/S Novo , Major Shareholder of AnaptysBio Inc (NASDAQ:ANAB) reportedly Sold 491,294 shares of the company’s stock at an average price of 21.12 for a total transaction amount of $10,376,129.28 SEC Form

Insider Trading History For AnaptysBio Inc (NASDAQ:ANAB)

  • On 1/31/2017 Nicholas Lydon, Director, bought 16,666 with an average share price of $15.00 per share and the total transaction amounting to $249,990.00.View SEC Filing
  • On 1/31/2017 Healthcare Vii L.P. Frazier, Major Shareholder, bought 400,000 with an average share price of $15.00 per share and the total transaction amounting to $6,000,000.00.View SEC Filing
  • On 7/26/2017 Ventures Vii L P Avalon, Major Shareholder, sold 37,040 with an average share price of $24.35 per share and the total transaction amounting to $901,924.00.View SEC Filing
  • On 8/3/2017 Holdings A/S Novo, Major Shareholder, sold 70,706 with an average share price of $23.31 per share and the total transaction amounting to $1,648,156.86.View SEC Filing
  • On 8/7/2017 Holdings A/S Novo, Major Shareholder, sold 491,294 with an average share price of $21.12 per share and the total transaction amounting to $10,376,129.28.View SEC Filing
  • Analyst Ratings For AnaptysBio Inc (NASDAQ:ANAB)
    These are 5 Buy Ratings .
    The current consensus rating for AnaptysBio Inc (NASDAQ:ANAB) is Buy (Score: 3.00) with a consensus target price of $35.60 , a potential (65.35% upside)

    Analyst Ratings History For AnaptysBio Inc (NASDAQ:ANAB)

    • On 3/29/2017 Wedbush Lower Price Target of rating Outperform with a price target of $33.00 to $28.00
    • On 3/31/2017 JMP Securities Reiterated Rating Outperform with a price target of $45.00
    • On 4/18/2017 Credit Suisse Group Reiterated Rating Outperform with a price target of $34.00
    • On 5/2/2017 Stifel Nicolaus Boost Price Target of rating Buy with a price target of $30.00 to $35.00
    • On 7/10/2017 Robert W. Baird Initiated Coverage of rating Outperform to Outperform with a price target of $36.00

    Recent Trading Activity for AnaptysBio Inc (NASDAQ:ANAB)
    Shares of AnaptysBio Inc closed the previous trading session at 21.53 down -1.25 -5.49% with 128,321 shares trading hands.